Drugs Containing Excipient (Inactive Ingredient) MAGNESIUM ALUMINOMETASILICATE

« Back to Dashboard

Branded drugs containing MAGNESIUM ALUMINOMETASILICATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kowa Pharmaceuticals America Inc	LIVALO	pitavastatin calcium	66869-104	MAGNESIUM ALUMINOMETASILICATE TYPE IB

Generic drugs containing MAGNESIUM ALUMINOMETASILICATE excipient

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	atorvastatin calcium	0480-3588	MAGNESIUM ALUMINOMETASILICATE
AvKARE	zolmitriptan	42291-998	MAGNESIUM ALUMINOMETASILICATE TYPE I-A
Jubilant Cadista Pharmacuticals Inc	risperidone	59746-010	MAGNESIUM ALUMINOMETASILICATE TYPE I-A
Jubilant Cadista Pharmacuticals Inc	zolmitriptan	59746-461	MAGNESIUM ALUMINOMETASILICATE TYPE I-A
St Mary's Medical Park Pharmacy	atorvastatin calcium	60760-979	MAGNESIUM ALUMINOMETASILICATE TYPE I-A
NuCare PharmaceuticalsInc	atorvastatin calcium	68071-2302	MAGNESIUM ALUMINOMETASILICATE TYPE I-A
NuCare PharmaceuticalsInc	atorvastatin calcium	68071-4962	MAGNESIUM ALUMINOMETASILICATE TYPE I-A

Magnesium Aluminometasilicate Market Dynamics and Financial Trajectory

Last updated: August 4, 2026

Magnesium aluminometasilicate is a specialized pharmaceutical excipient used in tablets, capsules, lipid-based formulations, solid dispersions, and moisture-sensitive drug products. The market is small relative to bulk excipients such as microcrystalline cellulose, lactose, and croscarmellose sodium, but it has higher technical value because its porous, high-surface-area structure can improve flow, compressibility, adsorption, drug loading, and dissolution.

Fuji Chemical Industries’ Neusilin product family is the best-known commercial platform. Standalone market revenue is not publicly reported by major suppliers, so financial analysis must rely on application demand, supplier disclosures, pharmaceutical formulation trends, and competitive substitution.

What is magnesium aluminometasilicate used for in pharmaceuticals?

Magnesium aluminometasilicate is a synthetic, amorphous aluminosilicate used as a multifunctional excipient. It is distinct from magnesium aluminum silicate, a clay-based suspending and thickening agent used in different formulation applications.

Attribute	Magnesium aluminometasilicate
Primary role	Adsorbent, carrier, compression aid, stabilizer
Typical dosage forms	Immediate-release tablets, capsules, powders, lipid formulations
Key formulation benefit	High surface area and porous particle structure
Main commercial platform	Neusilin grades
Principal supplier	Fuji Chemical Industries
Pharmacopoeial status	Recognized as a pharmaceutical excipient in applicable compendial and regulatory frameworks
Regulatory category	Inactive ingredient, not an active pharmaceutical ingredient
Typical customer	Generic-drug, specialty-pharma, contract-development and consumer-health manufacturers

The material can adsorb oils, liquid drugs, and poorly flowing active ingredients while remaining suitable for solid oral dosage forms. In tablets, it can improve powder flow, reduce sticking, support direct compression, and increase the physical stability of formulations.

Fuji markets several Neusilin grades with different particle sizes, pore structures, flow properties, and compression profiles. US2 and USF are commonly associated with tablet and capsule development, while other grades address liquid adsorption, lipid formulations, and specialized processing requirements.[1]

How large is the magnesium aluminometasilicate market?

No audited public market-size series isolates magnesium aluminometasilicate from the broader pharmaceutical-excipients market. Supplier financial statements generally report corporate or business-segment revenue rather than sales of individual excipients.

The commercial market is best characterized as a high-value niche within functional pharmaceutical excipients. Its economics differ from bulk excipients in four ways:

1. The material is purchased for performance rather than simply for volume.
2. Qualification and formulation work create switching costs.
3. Demand is linked to difficult APIs and complex oral formulations.
4. Supplier concentration is higher than in commodity excipients.

The addressable market includes pharmaceutical products using magnesium aluminometasilicate as a formulation aid, but not every approved product identifies the excipient in a way that permits reliable market-volume aggregation. FDA Inactive Ingredient Database entries provide regulatory precedent but do not disclose commercial consumption or supplier market share.[2]

Market-position estimate by application

Application	Demand outlook	Commercial rationale
Immediate-release tablets	Stable to positive	Direct compression, flow improvement and tablet robustness
Poorly soluble APIs	Positive	Adsorption, amorphous stabilization and dissolution enhancement
Lipid-based formulations	Positive	Conversion of oils and liquid formulations into solid dosage forms
Moisture-sensitive drugs	Positive	Moisture adsorption and improved physical stability
Consumer-health products	Moderate	Powder handling, odor masking and liquid adsorption
Parenteral products	Limited	Lower relevance than oral solid dosage forms
Biologics and biosimilars	Limited direct exposure	More relevant to oral small-molecule products than injectable biologics

What is driving demand for magnesium aluminometasilicate?

Growth in generic oral solid dosage products

Generic manufacturers increasingly use formulation platforms that can handle APIs with poor flow, low dose, high hydrophobicity, or weak compressibility. Magnesium aluminometasilicate can reduce the need for multiple separate formulation aids, improving process design and reducing tablet manufacturing problems.

Its value is highest when it solves a specific manufacturing or bioavailability problem. It is less likely to displace low-cost fillers in uncomplicated, high-volume tablets.

Poorly soluble drug development

Poor aqueous solubility remains a major development issue for small-molecule drugs. Porous aluminosilicates can act as carriers for liquid or dissolved APIs and can support amorphous or adsorbed drug systems. They are used alongside techniques such as spray drying, hot-melt processing, self-emulsifying drug delivery systems, and wet granulation.

The excipient does not independently guarantee a bioavailability improvement. Its commercial use depends on demonstrated dissolution, stability, manufacturability, and bioequivalence performance.

Direct compression and continuous manufacturing

Direct compression reduces processing steps and can lower manufacturing costs, but it places greater demands on powder flow, segregation resistance, compactability, and content uniformity. Magnesium aluminometasilicate can support these properties in selected formulations.

Continuous manufacturing also increases demand for excipients with predictable particle and bulk properties. Batch-to-batch consistency, low variability, and supplier technical support become important purchasing criteria.

Lifecycle management

Innovator and generic companies can use the material in reformulations that target:

• Higher drug loading
• Smaller tablets
• Improved dissolution
• Better moisture stability
• Reduced tablet weight
• Conversion of liquid formulations into tablets or capsules
• New dosage forms for existing active ingredients

Lifecycle-management demand can be more profitable than standard commodity excipient demand because customers may pay for development support and validated performance.

Which companies supply magnesium aluminometasilicate?

Fuji Chemical Industries is the dominant visible commercial supplier through the Neusilin platform. The company positions Neusilin as a multifunctional excipient for pharmaceutical formulation, including adsorption, compression, solid dispersion, and lipid-based delivery applications.[1]

The competitive structure has three levels:

Competitive level	Examples	Competitive basis
Direct product competitors	Other synthetic porous silicates and aluminosilicates	Surface area, pore volume, flow and compression
Functional substitutes	Colloidal silicon dioxide, calcium silicate, magnesium silicate	Adsorption, flow improvement and liquid loading
Formulation-process substitutes	Spray drying, hot-melt extrusion, lipid delivery systems	Bioavailability and physical-stability objectives

Direct substitution is limited when a formulation has already been optimized around a particular pore structure or grade. Substitution is easier during early development, especially when the excipient is used only as a flow aid or adsorbent.

Supplier concentration creates both pricing power and supply-chain exposure. Pharmaceutical customers typically require qualification of particle size, elemental impurities, microbial quality, residual moisture, packaging, and change-control procedures before approving an alternative source.

What formulations are protected by magnesium aluminometasilicate?

The excipient itself generally does not create a standalone patent monopoly over a drug product. Patent protection usually attaches to the formulation, manufacturing process, drug-excipient ratio, dosage form, or therapeutic use.

Potentially protectable subject matter includes:

• A specific API adsorbed onto magnesium aluminometasilicate
• A defined drug-to-excipient ratio
• A solid dispersion or self-emulsifying formulation
• A controlled-release matrix
• A tablet with specified compression and dissolution characteristics
• A formulation that improves stability or bioavailability
• A manufacturing process using a selected Neusilin grade
• A combination of magnesium aluminometasilicate with polymers, surfactants, or disintegrants

A patent covering a formulation can create commercial barriers even when the excipient is broadly available. The strength of such claims depends on written-description support, claim breadth, comparative data, enablement, and whether the formulation delivers a measurable technical effect.

How strong is the patent estate for magnesium aluminometasilicate?

The core commercial value is more likely to reside in know-how, supplier qualification, grade-specific performance, and application patents than in a single active composition patent covering all magnesium aluminometasilicate.

Patent strength is therefore fragmented:

Protection type	Strategic value
Broad composition patent	Potentially high, but difficult to sustain if the material is established in the prior art
Grade-specific manufacturing patent	Can protect particle structure and performance
Drug formulation patent	Often the most relevant protection for a finished product
Process patent	Can delay competitive replication if process conditions are difficult to reproduce
Trade secret and know-how	Important for production consistency and customer support
Trademark protection	Supports product recognition but does not block equivalent materials

Patent expiration dates must be assessed at the individual formulation or manufacturing-patent level. There is no single Orange Book patent-expiration date for magnesium aluminometasilicate.

What is the FDA regulatory status of magnesium aluminometasilicate?

Magnesium aluminometasilicate is an excipient, not an independently approved drug. FDA regulatory status is determined through its use in specific finished drug products and through the agency’s inactive-ingredient framework.

The FDA Inactive Ingredient Database records excipient use by dosage form, route, and maximum potency where available. A prior listing can support regulatory precedent, but it does not automatically authorize every grade, route, concentration, or formulation.[2]

Relevant regulatory considerations include:

• Identity and compendial conformity
• Elemental impurities, including aluminum and magnesium-related specifications
• Particle-size distribution
• Specific surface area and pore characteristics
• Loss on drying and moisture control
• Microbial limits
• Residual processing materials
• Extractables and leachables where relevant
• Supplier change control
• Compatibility with the active ingredient and other excipients

The International Pharmaceutical Excipients Council’s good manufacturing-practice framework is relevant to supplier qualification and quality systems.[3] FDA and European regulators also expect excipient quality to be controlled through pharmaceutical quality systems, risk assessment, specification management, and documented supply-chain oversight.[4]

Does magnesium aluminometasilicate have Orange Book patents or Paragraph IV risk?

There is no Orange Book listing for magnesium aluminometasilicate as an excipient. Orange Book patents are listed against approved drug products, not against excipient materials as independent commercial products.[5]

Paragraph IV risk can arise only when a generic applicant challenges a listed patent covering a finished formulation that uses magnesium aluminometasilicate. The relevant questions are:

1. Is the excipient specifically required by a listed formulation patent?
2. Does the generic use the same grade or a non-infringing substitute?
3. Are the patent claims directed to composition, process, dissolution, or method of treatment?
4. Can the generic demonstrate bioequivalence without practicing the claimed formulation?
5. Is the patent listed for the reference drug and still enforceable?

A generic applicant can often avoid excipient-related patent claims by changing the grade, ratio, manufacturing process, or carrier system, subject to bioequivalence and quality requirements. Formulation patents with narrow structural or performance limitations may be more vulnerable to design-around strategies than patents covering a broad therapeutic method.

What patent litigation and settlement risks affect the market?

The excipient market has no single litigation framework comparable to a branded drug’s Orange Book estate. Litigation risk is product-specific.

The principal legal risks are:

• Infringement claims over drug-excipient combinations
• Process-patent claims involving adsorption or solidification
• Trade-secret disputes involving grade manufacture
• Supplier qualification disputes
• Regulatory exclusivity disputes involving a finished drug
• Contract claims after excipient changes or supply interruption

Settlement agreements involving a specific drug may restrict launch timing, formulation design, or manufacturing methods. They do not necessarily restrict sales of magnesium aluminometasilicate to other customers.

When does generic entry affect magnesium aluminometasilicate demand?

Generic entry usually increases demand for specialized excipients when the generic must match a difficult reference product or when the API has poor manufacturability. The effect is weaker when generic competition triggers aggressive cost reduction and substitution toward commodity excipients.

Generic-launch scenarios

Scenario	Effect on excipient demand
Complex tablet with poor flow or low solubility	Positive; formulation performance has high value
Simple high-volume immediate-release tablet	Mixed; price pressure favors lower-cost substitutes
Lipid-based or liquid-to-solid formulation	Positive; technical functionality limits substitution
Narrow formulation patent	Positive for incumbent if protected; potential delay for generic
Successful design-around	Demand may shift among competing excipients
Multiple qualified suppliers	Lower prices and weaker supplier bargaining power

What is the financial trajectory for magnesium aluminometasilicate?

The financial trajectory is structurally positive but not comparable to a blockbuster pharmaceutical market. Revenue growth depends on volume expansion in oral solid dosage products and on continued adoption in complex formulation work.

Base-case trajectory

The base case is moderate growth driven by:

• Generic and specialty oral-dose development
• Poor-solubility formulation programs
• Lifecycle reformulation
• Demand for direct-compression excipients
• Greater use of solid and lipid-based delivery platforms
• Outsourced formulation development by contract manufacturers

Upside case

The strongest upside would come from broad adoption in commercial products using amorphous or adsorbed drug systems, particularly where the excipient enables a smaller tablet, higher drug loading, or improved stability. Qualification in multiple products by large pharmaceutical customers can create recurring demand because excipient changes after approval require regulatory assessment and manufacturing revalidation.

Downside case

The main downside risks are:

• Replacement by lower-cost silicates or conventional fillers
• Limited supplier competition
• Customer resistance to premium pricing
• Difficult elemental-impurity assessments
• Formulation failure during scale-up
• Weak adoption outside technically demanding products
• Concentration of demand in a small number of pharmaceutical programs

No public company discloses a standalone magnesium aluminometasilicate revenue line. Financial exposure is therefore indirect. For Fuji Chemical Industries, the product contributes to the broader pharmaceutical excipient and formulation-technology portfolio rather than representing a separately reported financial segment.

How does magnesium aluminometasilicate compare with competing excipients?

Excipient	Main advantage	Limitation relative to magnesium aluminometasilicate
Microcrystalline cellulose	Low cost and strong compression	Less effective for liquid adsorption and some poorly soluble APIs
Colloidal silicon dioxide	Flow and moisture control	Weaker compression contribution and different handling profile
Calcium silicate	High adsorption capacity	May require different tablet-processing conditions
Magnesium stearate	Lubrication	Not a substitute for porous carrier functionality
Crospovidone	Disintegration	Does not provide the same adsorption or liquid-loading role
Lactose	Low-cost filler and diluent	Limited functionality for oils and highly hydrophobic APIs
Starch-based excipients	Low cost and established use	Often less effective for specialized adsorption applications

Magnesium aluminometasilicate competes on formulation performance, not on raw-material price. Its commercial position is strongest when it replaces several functional excipients or solves a problem that conventional fillers cannot address.

What manufacturing and intellectual-property barriers exist?

Manufacturing requires control of the material’s amorphous structure, porosity, particle-size distribution, bulk density, moisture, and compression behavior. Small differences in these parameters can affect drug loading, flow, tablet hardness, dissolution, and stability.

The principal barriers are:

• Process control for reproducible porosity
• Qualification of raw materials
• Control of elemental impurities
• Scale-up consistency
• Customer-specific grade selection
• Regulatory documentation
• Stability data in the intended formulation
• Long qualification cycles
• Limited availability of equivalent commercial grades

These barriers support supplier retention even when broad patent protection is limited. Pharmaceutical companies often prefer an approved and technically supported grade over an unqualified lower-cost alternative.

Key Takeaways

• Magnesium aluminometasilicate is a specialized, multifunctional pharmaceutical excipient with the strongest demand in complex oral solid formulations.
• Fuji Chemical Industries’ Neusilin platform is the leading visible commercial product family.
• Standalone market size, supplier revenue, and market share are not publicly disclosed.
• Growth is tied to generic oral dosage products, poorly soluble APIs, direct compression, lipid-based delivery, and lifecycle reformulation.
• The product competes against porous silicates, colloidal silicon dioxide, calcium silicate, and conventional fillers.
• Its commercial moat comes from grade-specific performance, formulation know-how, quality systems, and customer qualification rather than a single Orange Book patent.
• FDA regulatory exposure is product-specific. The excipient has no independent drug approval or Orange Book patent listing.
• Paragraph IV risk can arise only through patents covering a finished drug formulation or manufacturing process.
• Financial upside is greatest when the material becomes embedded in approved, technically complex products with high switching costs.
• Price pressure is strongest in simple, high-volume tablets where conventional fillers can meet performance requirements.

FAQs

Is magnesium aluminometasilicate the same as magnesium aluminum silicate?

No. Magnesium aluminometasilicate is a synthetic porous aluminosilicate used primarily for adsorption, compression, and drug-carrier functions. Magnesium aluminum silicate is generally a clay-based excipient used as a suspending, thickening, or rheology-modifying agent.

Is Neusilin a generic name or a trademark?

Neusilin is a commercial product family and trademark associated with Fuji Chemical Industries. Magnesium aluminometasilicate is the material or excipient description.

Can magnesium aluminometasilicate improve the solubility of a drug?

It can improve apparent dissolution or drug dispersion by adsorbing an API, supporting an amorphous state, or converting a liquid formulation into a solid carrier system. The result depends on the API, grade, loading level, manufacturing method, and stability profile.

Is magnesium aluminometasilicate suitable for biologic drugs?

Its principal commercial relevance is in small-molecule oral formulations. It has limited direct relevance to injectable biologics and biosimilars, although it may have niche utility in oral delivery research or specialized biologic formulations.

Can a generic manufacturer replace magnesium aluminometasilicate without regulatory risk?

Not automatically. A replacement may require formulation development, comparative dissolution work, stability studies, bioequivalence assessment, supplier qualification, and regulatory documentation. The legal risk also depends on whether a drug patent claims the specific excipient, grade, ratio, or manufacturing process.

References

1. Fuji Chemical Industries Co., Ltd. (n.d.). Neusilin: Pharmaceutical excipient for solid dosage formulations. Fuji Chemical Industries.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. Center for Drug Evaluation and Research.

3. International Pharmaceutical Excipients Council. (2017). Good manufacturing practices guide for pharmaceutical excipients. IPEC.

4. European Medicines Agency. (2015). Guideline on the risk-based approach according to annex I of Directive 2001/83/EC applied to excipients of medicinal products for human use. EMA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.